Oxford Instruments plc has acquired Medical Imaging Resources Inc. (MIR). MIR specializes in the build, lease and service of mobile medical imaging labs.
CVRx Inc. announced that positive results from the 'Barostim Therapy for Heart Failure' randomized, controlled clinical trial were presented at the ESC-Heart Failure 2015 Annual Conference in a late-breaking trial session. Results were presented by Prof. Jochen MĂĽller-Ehmsen, M.D., Ph.D., from Asklepios Hospital Altona in Hamburg, Germany.
With the recent innovation of flexible microelectronic sensor circuits that can be made from bioresorbable materials, it is now possible to create “electronic stents” to monitor a treated lesion site inside a patient’s artery. A Korean-led team recently published their research on the first device of this kind, showing proof of concept in the American Chemical Society journal ACS Nano.[1]
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
The U.S. Food and Drug Administration (FDA) has cleared the InvisionECG technology from InvisionHeart. The mobile electrocardiogram (ECG) technology uses a secure cloud-based, healthcare IT platform to capture and manage 12-lead ECGs.
A virtual-heart platform proposed by Stony Brook University researchers and colleagues has received funding from the National Science Foundation (NSF) in the amount of $4.2 million over five years. The platform was designed to improve and accelerate medical-device development and testing.
OrbusNeich has announced that the first U.S. patient has been enrolled in the HARMONEE (Harmonized Assessment by Randomized, Multi-center Study of OrbusNEich's COMBO StEnt) stent study. The study is being conducted under the framework of the joint Japan-U.S. Harmonization-By-Doing (HBD) initiative and will support the company's planned application for Shonin approval in Japan and to meet the feasibility trial requirements in the U.S.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Kareo announced the launch of its Apple Watch App. This most recent innovation extends the functionality of the company’s electronic health record (EHR) to Apple Watch, streamlining care delivery and enhancing the patient experience by improving communications, reducing patient wait times and increasing practice efficiency.
Medic Vision Imaging Solutions Ltd. announced the introduction and availability of SafeCT Dose Reporting. Healthcare facilities can now, for the first time, use a single software platform to meet their low dose computed tomography (CT) imaging needs while also conforming to CT dose monitoring and reporting standards.
A microsupercapacitor designed by scientists at Rice University that may find its way into personal and even wearable electronics is getting an upgrade. The laser-induced graphene device benefits greatly when boron becomes part of the mix.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Shockwave Medical announced $40 million in funding, co-led by returning investor Sofinnova Partners and new investor Venrock. Also participating were RA Capital, Deerfield, Sectoral Asset Management, Ally Bridge Group and two undisclosed large-cap strategic investors.
Dassault Systèmes announced during its SIMULIA Community Conference that the first heart model from its “Living Heart Project” will be commercially available on May 29, 2015. Powered by Dassault Systèmes’ 3DEXPERIENCE platform’s realistic simulation applications, the commercial, high-fidelity, scientifically validated 3-D simulator of a four-chamber human heart is the first product of its kind. With this model, device manufacturers, researchers and medical professionals will be able to perform virtual tests and visualize the heart’s response in ways that are not possible with traditional physical testing.
A new study evaluating the Boston Scientific Lotus Valve System demonstrated an extremely low rate of paravalvular aortic regurgitation (leakage) for a transcatheter aortic replacement valve. Study data also showed a cardiovascular mortality rate of less than 2 percent at 30 days.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Privately-held company Arterial Remodeling Technologies (ART) announced CE Mark clearance for its next-generation drug-free, pure bioresorbable scaffold used to treat coronary artery disease. The CE Mark was achieved following the completion of extensive pre-clinical research — this included up to three-years of follow-up, and supportive clinical results from leading coronary angioplasty centres such as the Hôpital Européen Georges Pompidou in Paris and investigators such as Jean Fajadet, M.D., at the Clinique Pasteur in Toulouse.
At EuroPCR 2015, Mitralign presented updates on its mitral and tricuspid valve repair systems, including a presentation on six-month data on its Mitral system.
Edwards Lifesciences Corp. announced that 30-day outcomes for intermediate-risk patients treated transfemorally with the SAPIEN 3 transcatheter aortic valve demonstrated very low mortality and stroke rates, and no severe paravalvular leaks. These independently adjudicated data from centers in Europe and Canada are consistent with the outcomes recently reported in a similar study of 1,000 patients treated at 51 centers in the United States. The study was presented at EuroPCR 2015 by Alec Vahanian, M.D., chair of the cardiology department at Bichat University Hospital, Paris.